129 related articles for article (PubMed ID: 16344278)
1. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Lin JK; Tan EC; Yang MC
Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
[TBL] [Abstract][Full Text] [Related]
3. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Ward SE; Kaltenthaler E; Cowan J; Marples M; Orr B; Seymour MT
Br J Cancer; 2006 Jul; 95(1):27-34. PubMed ID: 16804526
[TBL] [Abstract][Full Text] [Related]
4. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P
Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698
[TBL] [Abstract][Full Text] [Related]
5. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Almond J; Ralston S
Br J Cancer; 2007 May; 96(9):1489; author reply 1490. PubMed ID: 17437019
[No Abstract] [Full Text] [Related]
6. A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Weaver A; Love SB; Larsen M; Shanyinde M; Waters R; Grainger L; Shearwood V; Brooks C; Gibson O; Young AM; Tarassenko L
Support Care Cancer; 2014 Oct; 22(10):2677-85. PubMed ID: 24771299
[TBL] [Abstract][Full Text] [Related]
7. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.
Borras JM; Sanchez-Hernandez A; Navarro M; Martinez M; Mendez E; Ponton JL; Espinas JA; Germa JR
BMJ; 2001 Apr; 322(7290):826. PubMed ID: 11290635
[TBL] [Abstract][Full Text] [Related]
8. Inappropriate continuation of medication when patients are admitted acutely: the example of capecitabine.
Booth JA; Booth C; Crawford SM
Clin Med (Lond); 2011 Oct; 11(5):511. PubMed ID: 22034726
[No Abstract] [Full Text] [Related]
9. A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs.
Wetzel S; Fidel J; Whittington D; Villarino NF
BMC Vet Res; 2024 Jan; 20(1):36. PubMed ID: 38297307
[TBL] [Abstract][Full Text] [Related]
10. A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
Brittain EH; Fay MP; Follmann DA
Biostatistics; 2012 Sep; 13(4):637-49. PubMed ID: 22467938
[TBL] [Abstract][Full Text] [Related]
11. Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
Nouibi C; Cherif Chefchaouni A; Bechar H; Belahcen MJ; Rahali Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1708-1714. PubMed ID: 36637236
[TBL] [Abstract][Full Text] [Related]
12. Deprived social status is associated with decreased use of oral chemotherapy in patients with metastatic colorectal cancer: A retrospective cohort study on administrative databases in a French University Hospital.
Gautier G; Lucas M; Vermeulin T; Di Fiore F; Merle V
Pharmacol Res Perspect; 2021 Dec; 9(6):e00888. PubMed ID: 34766736
[TBL] [Abstract][Full Text] [Related]
13. Response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Hill C
Eur J Cancer; 2023 Aug; 189():112929. PubMed ID: 37327685
[No Abstract] [Full Text] [Related]
14. Oral Chemotherapy for Treatment of Lung Cancer.
Jonna S; Reuss JE; Kim C; Liu SV
Front Oncol; 2020; 10():793. PubMed ID: 32426292
[TBL] [Abstract][Full Text] [Related]
15. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
16. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
17. Patient preferences for oral versus intravenous palliative chemotherapy.
Liu G; Franssen E; Fitch MI; Warner E
J Clin Oncol; 1997 Jan; 15(1):110-5. PubMed ID: 8996131
[TBL] [Abstract][Full Text] [Related]
18. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Schønnemann K; Sandberg E; Aabo K; Jakobsen A
Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184
[TBL] [Abstract][Full Text] [Related]
19. The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey.
Rodriguez Castells M; Baraibar I; Ros J; Saoudi N; Salvà F; García A; Alcaraz A; Tabernero J; Élez E
Front Oncol; 2023; 13():1272561. PubMed ID: 37909013
[TBL] [Abstract][Full Text] [Related]
20. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.
Baryakova TH; Pogostin BH; Langer R; McHugh KJ
Nat Rev Drug Discov; 2023 May; 22(5):387-409. PubMed ID: 36973491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
